Kyrgyzstan has taken a significant step toward reducing its dependence on imported pharmaceuticals with the launch of domestic medicine production at the Aidan Pharma pharmaceutical plant. The facility has begun manufacturing its first batch of essential medications, including:
- Paracetamol (suspensions and tablets);
- Ibuprofen (suspensions);
- Acetylsalicylic acid (tablets); and
- Acyclovir (tablets).
The plant has the capacity to produce up to 10,000 packages of each of these medicines per day, offering an important boost to the country’s pharmaceutical industry.
In late 2023, Aidan Pharma began producing medical ethyl alcohol, which is now supplied to state hospitals and pharmacies. During a visit to the plant on January 10, Health Minister Alymkadyr Beishenaliev announced plans to expand the plant’s product range to 100 items by the end of this year. He also revealed that the company intends to begin exporting its products in the future.
“The plant’s products meet quality standards and have a low production cost, making them more affordable compared to imported medicines,” Beishenaliev noted.
The Kyrgyz government has prioritized reducing the country’s reliance on imported medications. In December 2024, the Cabinet of Ministers approved an investment agreement for a Kyrgyz-Chinese pharmaceutical project led by Standard Pharm Group. This initiative will focus on packaging pharmaceuticals and constructing a new pharmaceutical plant in Kyrgyzstan.
The project, which will be implemented in two stages over five years, is expected to attract over $41 million in investment. According to Minister of Economy and Commerce Bakyt Sydykov, the plant will manufacture a range of medicines, including:
- Nutritional infusions;
- Antibacterial, anti-inflammatory, and antipyretic medications;
- Analgesics;
- Hypoglycemic treatments; and
- Gastrointestinal drugs.
Most of these medicines are included in Kyrgyzstan’s List of Vital Medicines, a critical inventory of essential pharmaceuticals that are currently not produced domestically.
The development of Kyrgyzstan’s pharmaceutical industry marks a critical shift toward self-sufficiency in healthcare. By expanding domestic production, the government aims to make essential medications more accessible and affordable for its population while fostering economic growth through investment and exports.
